Skip to main content
OpenTrials
Completed

NCT Number: NCT02655354

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

The overarching goal of this UH2-UH3 proposal is to work with the NIH Health Care Systems Research Collaboratory to develop and implement a large scale, cluster randomized pragmatic clinical trial demonstration project that directly informs national trauma care system policy targeting injured patients with presentations of Posttraumatic Stress Disorder (PTSD) and related comorbidity. Each year in the United States (US), over 30 million individuals present to trauma centers, emergency departments, and other acute care medical settings for the treatment of physical injuries. Multiple chronic conditions including enduring PTSD, alcohol and drug use problems, depression and associated suicidal ideation, pain and somatic symptom amplification, and chronic medical conditions (e.g., hypertension, coronary artery disease, diabetes, and pulmonary diseases) are endemic among physical trauma survivors with and without traumatic brain injuries (TBI). Evidence-based, collaborative care/care management treatment models for PTSD and related comorbidities exist. These care management models have the potential to be flexibly implemented in order to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries; care management models may also be effective in mitigating the impact of the acute injury event on symptom exacerbations in the large subpopulation of injury survivors who already carry a substantial pre-injury burden of multiple chronic medical conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Posttraumatic Stress Disorder Alcohol-Related Disorders Behavior Behavioral Symptoms Brain Diseases Brain Injuries Central Nervous System Diseases Chemically-Induced Disorders Chronic Disease Cognition Disorders Cognitive Dysfunction Craniocerebral Trauma Depression Disease Attributes Mental Disorders Mild Cognitive Impairment Nervous System Diseases Neurocognitive Disorders Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Quality of Life Self-Injurious Behavior Signs and Symptoms Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Substance-Related Disorders Suicidal Ideation Suicide Trauma and Stressor Related Disorders Trauma, Nervous System Wounds and Injuries Wounds and Injury

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Honor Health, Scottsdale, Arizona, United States

Loading trial locations.

About this study

Primary Aims and Hypotheses

The primary aim of the UH3 period is to conduct a pragmatic randomized effectiveness trial of a collaborative care intervention targeting PTSD and comorbid conditions after acute care injury hospitalization. The investigation aims to determine if injured patients receiving the collaborative care intervention demonstrate significant reductions in PTSD symptoms when compared to control patients receiving care as usual. The study also aims to determine if the intervention patients when compared to control patients will demonstrate significant reductions in depressive symptoms, suicidal ideation, and alcohol use problems, and improvements in physical function. The primary hypothesis is that the intervention group when compared to the control group will demonstrate significant reductions in PTSD symptoms over the course of the year after injury. Secondary hypotheses are that intervention patients when compared to control patients will demonstrate, significant reductions in depressive symptoms, significant reductions in alcohol use problems, and improved post-injury physical function.

A Priori Secondary Analyses

The study team hypothesizes that a subgroup of patients will have persistent PTSD symptoms that will not remit over the longitudinal course of the investigation, regardless of randomization to intervention or control group conditions. The study team also anticipates that readily identifiable baseline clinical, injury and demographic characteristics will be associated with persistent PTSD symptoms over time (e.g., higher PTSD symptom levels, greater pre-injury trauma exposure, intentional injury including firearm related injury mechanisms and other characteristics such as unemployment, as well as other baseline factors). Derived from previous randomized clinical trials, a cumulative burden index has been developed from these baseline characteristics and will be adapted for the current investigation. The study team proposes a series of secondary analyses that adjust for and stratify by baseline characteristics that put patients at risk for persistent symptoms. It is hypothesized that these secondary analyses will identify a subgroup of intervention patients who are not at risk for persistent symptoms and who will demonstrate clinically and statistically significant treatment responses when compared to patients with similar baseline characteristics in the control condition. The study team also hypothesizes that the treatment effects will be greatest at the 1-6 month post-injury time points that are temporally correlated with the period of active intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient currently admitted to inpatient/emergency department for a traumatic injury

Exclusion criteria

  • Non-English speaking
  • Self-inflicted injury
  • Actively psychotic
  • Incarcerated or in custody
  • Less than 35 on PTSD Checklist
  • Less than 3 items on PTSD medical record screen
  • Less than 2 pieces of contact information

Treatment and study plan

Motivational Interviewing

Behavioral

Cognitive Behavioral Therapy Elements

Behavioral

Care management

Behavioral

Fluoxetine

Drug

Anti-depressant

Fluvoxamine

Drug

Anti-depressant

paroxetine

Drug

Anti-depressant

Sertraline

Drug

Anti-depressant

Citalopram

Drug

Anti-depressant

Venlafaxine

Drug

Anti-depressant

Duloxetine

Drug

Anti-depressant

mirtazapine

Drug

Anti-depressant

diphenhydramine

Drug

Sleep medication

Trazodone

Drug

Sleep medication

Prazosin

Drug

Sleep medication

Primary outcomes

  1. Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury

    Time frame: Baseline, 3-month, 6-month, 12-month

    The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD.

  2. Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury

    Time frame: Baseline, 3-month, 6-month, 12-month

    The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome.

  3. Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury

    Time frame: Baseline, 3-month, 6-month, 12-month

    The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome.

  4. Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury

    Time frame: Baseline, 3-month, 6-month, 12-month

    The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome.

Secondary outcomes

  1. Number of Participants With Suicidal Ideation

    Time frame: Baseline, 3-month, 6-month, 12-month

    Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome.

  2. Number of Participants Endorsing a Single Item That Assesses Opioid Use

    Time frame: Baseline, 3-month, 6-month, 12-month

    Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use.

  3. Cognitive Impairment Scale

    Time frame: Baseline, 3-month, 6-month, 12-month

    The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome.

  4. Brief Pain Inventory

    Time frame: Baseline, 3-month, 6-month, 12-month

    A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain.

  5. SF-36 Quality of Life

    Time frame: Baseline, 3-month, 6-month, 12-month

    The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health.

  6. TSOS Patient Satisfaction: Overall Health Care

    Time frame: Baseline, 3-month, 6-month, 12-month

    Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.

  7. Number of Participants Endorsing a Single Item That Assesses Stimulant Use

    Time frame: Baseline, 3-month, 6-month, 12-month

    Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use.

  8. Number of Participants Endorsing a Single Item That Assesses Marijuana Use

    Time frame: Baseline, 3-month, 6-month, 12-month

    Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use.

  9. TSOS Patient Satisfaction: Mental Health Care

    Time frame: Baseline, 3 Month, 6 Month, 12 Month

    Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied.

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • National Institute of Mental Health (NIMH)
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • National Institutes of Health (NIH)

Registry information

Acronym: TSOS6

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Jan 14, 2016
Registry last updated
Jul 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.